Annual EBIT
-$25.71 M
+$31.89 M+55.37%
December 31, 2023
Summary
- As of February 24, 2025, LSTA annual earnings before interest & taxes is -$25.71 million, with the most recent change of +$31.89 million (+55.37%) on December 31, 2023.
- During the last 3 years, LSTA annual EBIT has fallen by -$6.56 million (-34.28%).
- LSTA annual EBIT is now -11501.08% below its all-time high of -$221.60 thousand, reached on March 1, 1998.
Performance
LSTA EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$5.34 M
+$187.00 K+3.39%
September 30, 2024
Summary
- As of February 24, 2025, LSTA quarterly earnings before interest & taxes is -$5.34 million, with the most recent change of +$187.00 thousand (+3.39%) on September 30, 2024.
- Over the past year, LSTA quarterly EBIT has increased by +$689.00 thousand (+11.44%).
- LSTA quarterly EBIT is now -4220.65% below its all-time high of -$123.50 thousand, reached on March 1, 2003.
Performance
LSTA Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$23.48 M
+$628.00 K+2.60%
September 30, 2024
Summary
- As of February 24, 2025, LSTA TTM earnings before interest & taxes is -$23.48 million, with the most recent change of +$628.00 thousand (+2.60%) on September 30, 2024.
- Over the past year, LSTA TTM EBIT has increased by +$2.22 million (+8.65%).
- LSTA TTM EBIT is now -8627.24% below its all-time high of -$269.10 thousand, reached on March 1, 2000.
Performance
LSTA TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
LSTA EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +55.4% | +11.4% | +8.7% |
| 3 y3 years | -34.3% | +11.4% | +8.7% |
| 5 y5 years | -59.0% | +11.4% | +8.7% |
LSTA EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +55.4% | at high | +85.8% | at high | +59.5% |
| 5 y | 5-year | -34.3% | +55.4% | -31.5% | +85.8% | -26.9% | +59.5% |
| alltime | all time | <-9999.0% | +73.3% | -4220.6% | +88.5% | -8627.2% | +75.6% |
Lisata Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.34 M(-3.4%) | -$23.48 M(-2.6%) |
| Jun 2024 | - | -$5.52 M(-16.3%) | -$24.11 M(-5.3%) |
| Mar 2024 | - | -$6.60 M(+9.6%) | -$25.46 M(-0.9%) |
| Dec 2023 | -$25.71 M(-55.4%) | -$6.03 M(+1.0%) | -$25.71 M(-2.0%) |
| Sep 2023 | - | -$5.96 M(-13.3%) | -$26.22 M(-54.8%) |
| Jun 2023 | - | -$6.88 M(+0.5%) | -$57.98 M(+0.3%) |
| Mar 2023 | - | -$6.84 M(+4.6%) | -$57.82 M(+0.4%) |
| Dec 2022 | -$57.60 M(+98.3%) | -$6.54 M(-82.7%) | -$57.60 M(-0.5%) |
| Sep 2022 | - | -$37.72 M(+461.3%) | -$57.91 M(+113.2%) |
| Jun 2022 | - | -$6.72 M(+1.5%) | -$27.16 M(-1.5%) |
| Mar 2022 | - | -$6.62 M(-3.3%) | -$27.58 M(-5.0%) |
| Dec 2021 | -$29.05 M(+51.7%) | - | - |
| Dec 2021 | - | -$6.85 M(-1.7%) | -$29.05 M(+5.1%) |
| Sep 2021 | - | -$6.97 M(-2.5%) | -$27.65 M(+6.2%) |
| Jun 2021 | - | -$7.15 M(-11.6%) | -$26.03 M(+12.3%) |
| Mar 2021 | - | -$8.09 M(+48.5%) | -$23.17 M(+21.0%) |
| Dec 2020 | -$19.14 M(-4.7%) | -$5.45 M(+1.8%) | -$19.14 M(+1.9%) |
| Sep 2020 | - | -$5.35 M(+24.7%) | -$18.78 M(+1.5%) |
| Jun 2020 | - | -$4.29 M(+5.8%) | -$18.50 M(-5.4%) |
| Mar 2020 | - | -$4.06 M(-20.2%) | -$19.56 M(-2.7%) |
| Dec 2019 | -$20.09 M(+24.3%) | -$5.08 M(+0.2%) | -$20.09 M(+8.2%) |
| Sep 2019 | - | -$5.07 M(-5.1%) | -$18.57 M(+8.9%) |
| Jun 2019 | - | -$5.35 M(+16.4%) | -$17.04 M(+8.1%) |
| Mar 2019 | - | -$4.59 M(+29.1%) | -$15.77 M(-2.4%) |
| Dec 2018 | -$16.16 M(-40.8%) | -$3.56 M(+0.2%) | -$16.16 M(-18.3%) |
| Sep 2018 | - | -$3.55 M(-12.9%) | -$19.79 M(-10.8%) |
| Jun 2018 | - | -$4.08 M(-18.2%) | -$22.19 M(-14.1%) |
| Mar 2018 | - | -$4.98 M(-30.7%) | -$25.82 M(-5.5%) |
| Dec 2017 | -$27.32 M(-7.3%) | -$7.18 M(+20.7%) | -$27.32 M(+6.6%) |
| Sep 2017 | - | -$5.95 M(-22.7%) | -$25.62 M(+0.9%) |
| Jun 2017 | - | -$7.71 M(+19.0%) | -$25.39 M(+1.2%) |
| Mar 2017 | - | -$6.48 M(+18.0%) | -$25.08 M(-15.5%) |
| Dec 2016 | -$29.48 M(-69.3%) | -$5.49 M(-4.1%) | -$29.68 M(-58.0%) |
| Sep 2016 | - | -$5.72 M(-22.6%) | -$70.57 M(-6.7%) |
| Jun 2016 | - | -$7.40 M(-33.2%) | -$75.64 M(-14.6%) |
| Mar 2016 | - | -$11.07 M(-76.1%) | -$88.56 M(-7.9%) |
| Dec 2015 | -$96.13 M(+75.4%) | -$46.38 M(+329.8%) | -$96.13 M(+56.8%) |
| Sep 2015 | - | -$10.79 M(-46.9%) | -$61.31 M(-9.1%) |
| Jun 2015 | - | -$20.31 M(+9.0%) | -$67.46 M(+12.9%) |
| Mar 2015 | - | -$18.63 M(+61.1%) | -$59.76 M(+9.0%) |
| Dec 2014 | -$54.81 M(+42.7%) | -$11.56 M(-31.8%) | -$54.81 M(-1.4%) |
| Sep 2014 | - | -$16.95 M(+34.3%) | -$55.61 M(+16.3%) |
| Jun 2014 | - | -$12.62 M(-7.8%) | -$47.80 M(+10.4%) |
| Mar 2014 | - | -$13.69 M(+10.8%) | -$43.29 M(+12.7%) |
| Dec 2013 | -$38.42 M(+10.7%) | -$12.36 M(+35.3%) | -$38.42 M(+0.2%) |
| Sep 2013 | - | -$9.13 M(+12.6%) | -$38.36 M(+2.6%) |
| Jun 2013 | - | -$8.11 M(-8.0%) | -$37.39 M(+3.7%) |
| Mar 2013 | - | -$8.82 M(-28.3%) | -$36.07 M(+3.9%) |
| Dec 2012 | -$34.70 M(+8.7%) | -$12.29 M(+50.6%) | -$34.70 M(+24.5%) |
| Sep 2012 | - | -$8.16 M(+20.3%) | -$27.88 M(+3.5%) |
| Jun 2012 | - | -$6.79 M(-9.0%) | -$26.94 M(-9.1%) |
| Mar 2012 | - | -$7.46 M(+36.3%) | -$29.64 M(+0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$31.92 M(+73.8%) | -$5.47 M(-24.4%) | -$29.51 M(-3.5%) |
| Sep 2011 | - | -$7.23 M(-23.8%) | -$30.58 M(+5.3%) |
| Jun 2011 | - | -$9.48 M(+29.5%) | -$29.05 M(+26.7%) |
| Mar 2011 | - | -$7.33 M(+12.0%) | -$22.92 M(+24.8%) |
| Dec 2010 | -$18.37 M(-29.1%) | -$6.54 M(+14.8%) | -$18.37 M(-23.4%) |
| Sep 2010 | - | -$5.70 M(+69.9%) | -$23.99 M(-6.0%) |
| Jun 2010 | - | -$3.35 M(+21.0%) | -$25.51 M(-5.0%) |
| Mar 2010 | - | -$2.77 M(-77.2%) | -$26.84 M(+3.5%) |
| Dec 2009 | -$25.89 M(+180.4%) | -$12.17 M(+68.5%) | -$25.93 M(+60.2%) |
| Sep 2009 | - | -$7.22 M(+54.0%) | -$16.19 M(+48.7%) |
| Jun 2009 | - | -$4.69 M(+152.4%) | -$10.89 M(+27.2%) |
| Mar 2009 | - | -$1.86 M(-23.5%) | -$8.56 M(-7.2%) |
| Dec 2008 | -$9.23 M(-11.6%) | -$2.43 M(+26.5%) | -$9.23 M(+1.0%) |
| Sep 2008 | - | -$1.92 M(-18.7%) | -$9.14 M(-20.8%) |
| Jun 2008 | - | -$2.36 M(-6.5%) | -$11.54 M(+3.6%) |
| Mar 2008 | - | -$2.52 M(+7.9%) | -$11.14 M(+6.8%) |
| Dec 2007 | -$10.44 M(+122.5%) | -$2.34 M(-45.9%) | -$10.44 M(+6.3%) |
| Sep 2007 | - | -$4.32 M(+120.9%) | -$9.81 M(+51.2%) |
| Jun 2007 | - | -$1.96 M(+7.6%) | -$6.49 M(+16.5%) |
| Mar 2007 | - | -$1.82 M(+5.9%) | -$5.57 M(+18.8%) |
| Dec 2006 | -$4.69 M(+193.0%) | -$1.72 M(+72.1%) | -$4.69 M(+35.4%) |
| Sep 2006 | - | -$998.00 K(-3.8%) | -$3.46 M(+15.2%) |
| Jun 2006 | - | -$1.04 M(+10.7%) | -$3.01 M(+29.3%) |
| Mar 2006 | - | -$937.40 K(+91.1%) | -$2.33 M(+45.3%) |
| Dec 2005 | -$1.60 M(+8.6%) | -$490.50 K(-9.5%) | -$1.60 M(+16.6%) |
| Sep 2005 | - | -$542.10 K(+52.3%) | -$1.37 M(+10.0%) |
| Jun 2005 | - | -$355.90 K(+67.6%) | -$1.25 M(-4.4%) |
| Mar 2005 | - | -$212.40 K(-19.1%) | -$1.31 M(-11.4%) |
| Dec 2004 | -$1.47 M(+64.9%) | -$262.60 K(-37.1%) | -$1.47 M(-6.8%) |
| Sep 2004 | - | -$417.40 K(+1.0%) | -$1.58 M(+16.2%) |
| Jun 2004 | - | -$413.30 K(+8.5%) | -$1.36 M(+18.1%) |
| Mar 2004 | - | -$381.00 K(+3.1%) | -$1.15 M(+28.8%) |
| Dec 2003 | -$894.30 K(-22.2%) | -$369.40 K(+87.7%) | -$894.40 K(+1.4%) |
| Sep 2003 | - | -$196.80 K(-3.9%) | -$882.10 K(-3.1%) |
| Jun 2003 | - | -$204.70 K(+65.7%) | -$910.30 K(+0.4%) |
| Mar 2003 | - | -$123.50 K(-65.4%) | -$906.50 K(-21.1%) |
| Dec 2002 | -$1.15 M(-28.4%) | -$357.10 K(+58.7%) | -$1.15 M(-7.4%) |
| Sep 2002 | - | -$225.00 K(+12.0%) | -$1.24 M(-11.5%) |
| Jun 2002 | - | -$200.90 K(-45.2%) | -$1.40 M(-9.8%) |
| Mar 2002 | - | -$366.30 K(-18.5%) | -$1.55 M(-0.8%) |
| Dec 2001 | -$1.61 M(-36.2%) | -$449.50 K(+16.6%) | -$1.57 M(-12.8%) |
| Sep 2001 | - | -$385.60 K(+9.3%) | -$1.80 M(-26.4%) |
| Jun 2001 | - | -$352.90 K(-6.7%) | -$2.44 M(-5.1%) |
| Mar 2001 | - | -$378.20 K(-44.3%) | -$2.57 M(+4.4%) |
| Dec 2000 | -$2.52 M(+146.1%) | -$679.40 K(-34.0%) | -$2.46 M(+38.1%) |
| Sep 2000 | - | -$1.03 M(+113.1%) | -$1.78 M(+136.9%) |
| Jun 2000 | - | -$483.10 K(+79.5%) | -$752.20 K(+179.5%) |
| Mar 2000 | - | -$269.10 K | -$269.10 K |
| Dec 1999 | -$1.02 M(+138.8%) | - | - |
| Dec 1998 | -$428.20 K(+93.2%) | - | - |
| Mar 1998 | -$221.60 K(-11.9%) | - | - |
| Mar 1997 | -$251.60 K(-2.1%) | - | - |
| Mar 1996 | -$257.10 K | - | - |
FAQ
- What is Lisata Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Lisata Therapeutics?
- What is Lisata Therapeutics annual EBIT year-on-year change?
- What is Lisata Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Lisata Therapeutics?
- What is Lisata Therapeutics quarterly EBIT year-on-year change?
- What is Lisata Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Lisata Therapeutics?
- What is Lisata Therapeutics TTM EBIT year-on-year change?
What is Lisata Therapeutics annual earnings before interest & taxes?
The current annual EBIT of LSTA is -$25.71 M
What is the all time high annual EBIT for Lisata Therapeutics?
Lisata Therapeutics all-time high annual earnings before interest & taxes is -$221.60 K
What is Lisata Therapeutics annual EBIT year-on-year change?
Over the past year, LSTA annual earnings before interest & taxes has changed by +$31.89 M (+55.37%)
What is Lisata Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of LSTA is -$5.34 M
What is the all time high quarterly EBIT for Lisata Therapeutics?
Lisata Therapeutics all-time high quarterly earnings before interest & taxes is -$123.50 K
What is Lisata Therapeutics quarterly EBIT year-on-year change?
Over the past year, LSTA quarterly earnings before interest & taxes has changed by +$689.00 K (+11.44%)
What is Lisata Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of LSTA is -$23.48 M
What is the all time high TTM EBIT for Lisata Therapeutics?
Lisata Therapeutics all-time high TTM earnings before interest & taxes is -$269.10 K
What is Lisata Therapeutics TTM EBIT year-on-year change?
Over the past year, LSTA TTM earnings before interest & taxes has changed by +$2.22 M (+8.65%)